Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1467335 in non-proliferative diabetic retinopathy
2016-002971-91Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic retinopathy (NPDR) comparing BI 1467335 with Placebo (2 arms). Primary endpoints: Ocular safety (CTCAE ocular adverse events) and Systemic safety and tolerability. Started Aug 2017; status: completed.
02
Drugs
PXS-4728A
03
Conditions
diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2016-002971-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002971-91.